Subscribe for the newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
ViiV Healthcare
Sort By
Newest First
Sign in
1 / 1
1 / 1
HIV
ViiV Healthcare’s Injectable Formulation Dosed Every Two Months Shows Higher Efficacy than Daily Oral PrEP
GSK
PR-M05-20-NI-034-1543
May 22, 2020
HIV Treatment
ViiV Healthcare Reports Positive Phase III Study Results of Investigational, Long-acting, Injectable HIV-treatment Regimen Administered Every Two Months
GSK
PR-M08-19-NI-074
Aug 26, 2019
FDA Approval
GSK’s ViiV Healthcare Seeks FDA Approval for Combination HIV Therapy
Emilie Branch
Pharma's Almanac
PAO-M10-18-NI-029
Oct 29, 2018
